HRP20100674T1 - Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka - Google Patents
Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka Download PDFInfo
- Publication number
- HRP20100674T1 HRP20100674T1 HR20100674T HRP20100674T HRP20100674T1 HR P20100674 T1 HRP20100674 T1 HR P20100674T1 HR 20100674 T HR20100674 T HR 20100674T HR P20100674 T HRP20100674 T HR P20100674T HR P20100674 T1 HRP20100674 T1 HR P20100674T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- proportion
- active agent
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical class C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- JODIEZIJHKKWKN-UHFFFAOYSA-N 3-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=NC=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 JODIEZIJHKKWKN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmaceutski pripravak naznacen time da je tableta koja sadrzi p-toluensulfonsku kiselu sol 4{4-[3-(4-kloro-3-trifluorometilfenil)-ureido]-fenoksi}-piridin-2-karboksilne kiselina metil amida kao aktivno sredstvo koje ima udio od najmanje 55% tezinski pripravka. Patent sadrzi jos 19 patentnih zahtjeva.
Claims (20)
1. Farmaceutski pripravak naznačen time da je tableta koja sadrži p-toluensulfonsku kiselu sol 4{4-[3-(4-kloro-3-trifluorometilfenil)-ureido]-fenoksi}-piridin-2-karboksilne kiselina metil amida kao aktivno sredstvo koje ima udio od najmanje 55% težinski pripravka.
2. Farmaceutski pripravak prema zahtjevu 1 naznačen time da aktivno sredstvo ima udio od najmanje 75% težinski pripravka.
3. Farmaceutski pripravak prema zahtjevu 1 naznačen time da punilo ima udio od 3 do 20 %, sredstvo za raspadanje ima udio od 5 do 12 %, vezivo ima udio od 0.5 do 8 %, lubrikant ima udio od 0.2 do 0.8 % i surfaktant ima udio od 0.1 do 2 % težinski pripravka.
4. Farmaceutski pripravak prema zahtjevu 2 naznačen time da je mikrokristalinična celuloza kao punilo u udjelu od 3 do 20 %, kroskarmeloza natrij kao sredstvo za raspadanje u udjelu od 5 do 12 %, hipromelozu kao vezivo u udjelu od 0.5 do 8 %, magnezijev stearat kao lubrikant u udjelu od 0.2 do 8 % i natrijev lauril sulfat kao surfaktant u udjelu od 0.1 do 2 % težinski pripravka.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4 naznačen time da je tableta sa neposrednim otpuštanjem.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5 naznačen time da je aktivno sredstvo mikronizirano.
7. Farmaceutski pripravak prema zahtjevu 6 naznačen time da mikronizirani oblik ima veličinu čestica od 0.5 do 10 µm.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7 naznačen time da sadrži vodu u količini manjoj od ili jednakoj 6 % težinski pripravka.
9. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8 naznačen time da ima čvrstoću od više od 80 N.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9 naznačen time da je ovalna tableta sa najdužom dimenzijom manjom od ili jednakom 25 mm.
11. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9 naznačen time da je okrugla tableta sa promjerom manjim od ili jednakim 13 mm.
12. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 11 naznačen time da količina aktivnog sredstva je od 54 mg do 1096 mg.
13. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 12 naznačen time da je za oralnu primjenu.
14. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 13 naznačen time da je u kombinaciji s jednim ili više citotoksičnih sredstava, inhibitora transdukcije signala ili s drugim anti-karcinomskim sredstvima ili terapijama, kao i sa smjesama i njihovim kombinacijama.
15. Postupak proizvodnje farmaceutskog pripravka prema bilo kojem od zahtjeva 1 do 14 naznačen time da je aktivno sredstvo pomiješano s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari.
16. Postupak prema zahtjevu 15 naznačen time da:
a) aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar su mokro granulirane,
b) granulat je pomiješan sa lubrikantom i po izboru s jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari,
c) granulat je nakon miješanja podijeljen na pojedinačne jedinice,
d) te se produkt iz koraka c) po potrebi prevlači sa jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari.
17. Postupak prema bilo kojem od zahtjeva 15 ili 16 naznačen time da se produkt iz koraka c) prevlači sa jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari.
18. Postupak prema zahtjevu 15 naznačen time da su aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar pomiješane bez granulacije i direktno komprimirane u tablete.
19. Postupak prema zahtjevu 15 naznačen time da su aktivno sredstvo samo ili aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar tretirane postupkom suhe granulacije i zatim komprimirane u tablete.
20. Uporaba farmaceutskog pripravka prema bilo kojem od zahtjeva 1 do 14 naznačena time da je za proizvodnju lijeka za liječenje hiper-proliferativnih poremećaja kod sisavaca, uključujući rak.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65882705P | 2005-03-07 | 2005-03-07 | |
PCT/EP2006/001574 WO2006094626A1 (en) | 2005-03-07 | 2006-02-22 | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100674T1 true HRP20100674T1 (hr) | 2011-01-31 |
Family
ID=36507604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100674T HRP20100674T1 (hr) | 2005-03-07 | 2010-12-06 | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka |
Country Status (38)
Country | Link |
---|---|
US (2) | US9737488B2 (hr) |
EP (1) | EP1868579B1 (hr) |
JP (1) | JP5304241B2 (hr) |
KR (1) | KR101335932B1 (hr) |
CN (2) | CN101132779B (hr) |
AR (1) | AR054234A1 (hr) |
AT (1) | ATE482693T1 (hr) |
AU (1) | AU2006222365B2 (hr) |
BR (1) | BRPI0608840B8 (hr) |
CA (1) | CA2601955C (hr) |
CR (1) | CR9348A (hr) |
CU (1) | CU23821A3 (hr) |
CY (1) | CY1111065T1 (hr) |
DE (1) | DE602006017188D1 (hr) |
DK (1) | DK1868579T3 (hr) |
DO (1) | DOP2006000057A (hr) |
ES (1) | ES2351612T3 (hr) |
GT (1) | GT200600096A (hr) |
HK (2) | HK1118019A1 (hr) |
HN (1) | HN2006009702A (hr) |
HR (1) | HRP20100674T1 (hr) |
IL (1) | IL185517A (hr) |
MA (1) | MA29378B1 (hr) |
MX (1) | MX2007010856A (hr) |
MY (1) | MY162319A (hr) |
NO (1) | NO343834B1 (hr) |
NZ (1) | NZ561178A (hr) |
PE (1) | PE20061345A1 (hr) |
PL (1) | PL1868579T3 (hr) |
PT (1) | PT1868579E (hr) |
SG (1) | SG160364A1 (hr) |
SI (1) | SI1868579T1 (hr) |
TN (1) | TNSN07341A1 (hr) |
TW (1) | TWI324928B (hr) |
UA (1) | UA93673C2 (hr) |
UY (1) | UY29410A1 (hr) |
WO (1) | WO2006094626A1 (hr) |
ZA (1) | ZA200707638B (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
CA2475703C (en) | 2002-02-11 | 2016-12-20 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
DK1626714T3 (da) | 2003-05-20 | 2007-10-15 | Bayer Pharmaceuticals Corp | Dirarylurinstoffer mod sygdomme medieret af PDGFR |
ME00294B (me) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
NZ553804A (en) * | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
CA2627875A1 (en) * | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Combinations comprising sorafenib and interferon for the treatment of cancer |
WO2008008733A2 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008089389A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
NZ623495A (en) | 2008-05-15 | 2015-08-28 | Celgene Corp | Oral formulations of cytidine analogs and methods of use thereof |
EP2440531A2 (en) * | 2009-06-12 | 2012-04-18 | Ratiopharm GmbH | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
EP2528899B1 (en) * | 2010-01-29 | 2014-10-15 | Ranbaxy Laboratories Limited | Sorafenib dimethyl sulphoxide solvate |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
SG189038A1 (en) | 2010-10-01 | 2013-05-31 | Bayer Ip Gmbh | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
PL2806860T3 (pl) | 2012-01-23 | 2023-09-11 | Sandoz Ag | Kompozycja farmaceutyczna zawierająca krystaliczny tosylan sorafenibu |
US9540382B2 (en) | 2012-06-04 | 2017-01-10 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
EP3193877A4 (en) | 2014-08-07 | 2018-04-04 | Pharmacyclics LLC | Novel formulations of a bruton's tyrosine kinase inhibitor |
IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
WO2016182867A1 (en) * | 2015-05-14 | 2016-11-17 | Fmc Corporation | Method of making bleached microcrystalline cellulose |
WO2017159585A1 (ja) * | 2016-03-14 | 2017-09-21 | 参天製薬株式会社 | メグルミン又はその塩からなる防腐剤 |
CN106344530B (zh) * | 2016-09-30 | 2019-03-19 | 京津冀联创药物研究(北京)有限公司 | 一种索拉非尼组合物及其制备方法 |
JP7055820B2 (ja) | 2017-05-26 | 2022-04-18 | ブルーイン バイオサイエンシズ,インコーポレイテッド | 化学塞栓療法剤 |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
WO2018211336A2 (en) | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Solid dosage form containing sorafenib tosylate |
CA3118324A1 (en) | 2018-11-01 | 2020-05-07 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
US20220354951A1 (en) | 2019-08-02 | 2022-11-10 | Onehealthcompany, Inc. | Treatment of Canine Cancers |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3125359A (en) * | 1964-03-17 | Push-pull breakaway coupling | ||
NL121140C (hr) * | 1961-11-08 | |||
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
EP0841910A4 (en) | 1995-07-25 | 2006-09-13 | Smithkline Beecham Corp | INHIBITION OF A TRANSACYLASE INDEPENDENT OF COENZYME A (CoA) AND APOPTOSIS |
EA004771B1 (ru) | 1996-04-23 | 2004-08-26 | Вертекс Фармасьютикалз Инкорпорейтед | Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы |
ES2151467T3 (es) | 1997-05-23 | 2005-03-01 | Bayer Corporation | Arilureas para el tratamiento de enfermedades inflamatorias o inmunomoduladoras. |
ATE399007T1 (de) | 1997-05-23 | 2008-07-15 | Bayer Pharmaceuticals Corp | Raf kinase hemmer |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
JP2001526222A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | アリールおよびヘテロアリール置換複素環尿素を使用するp38キナーゼ活性の阻害 |
DE1041982T1 (de) | 1997-12-22 | 2001-06-07 | Bayer Corp., Pittsburgh | HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
DE1042305T1 (de) | 1997-12-22 | 2001-04-19 | Bayer Corp., Pittsburgh | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
TR200100918T2 (tr) | 1997-12-22 | 2001-06-21 | Bayer Corporation | Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi |
HUP0101704A3 (en) | 1997-12-22 | 2002-12-28 | Bayer Corp Pittsburgh | Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them |
CA2315646C (en) | 1997-12-22 | 2010-02-09 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20030087849A1 (en) | 2001-07-03 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HKR1 expression |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
RU2319693C9 (ru) * | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
ATE329583T1 (de) * | 2000-08-18 | 2006-07-15 | Pharmacia Corp | Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2441501C (en) | 2001-03-23 | 2010-09-14 | Bayer Corporation | Rho-kinase inhibitors |
DE60218445T2 (de) | 2001-04-20 | 2007-11-29 | Bayer Pharmaceuticals Corp., West Haven | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20030207914A1 (en) * | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
EP2295057B1 (en) | 2001-12-03 | 2013-01-23 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
CA2466762A1 (en) | 2001-12-04 | 2003-06-12 | Onyx Pharmaceuticals, Inc. | Raf-mek-erk pathway inhibitors to treat cancer |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
CA2475703C (en) * | 2002-02-11 | 2016-12-20 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
CN1318404C (zh) | 2002-02-11 | 2007-05-30 | 拜耳制药公司 | 作为激酶抑制剂的芳基脲类化合物 |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
WO2003101444A1 (en) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
CA2516624C (en) | 2003-02-28 | 2013-05-14 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders |
CA2516627A1 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
CA2516931C (en) | 2003-02-28 | 2014-09-09 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US6896863B2 (en) * | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
DK1626714T3 (da) | 2003-05-20 | 2007-10-15 | Bayer Pharmaceuticals Corp | Dirarylurinstoffer mod sygdomme medieret af PDGFR |
WO2005009367A2 (en) | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
ME00294B (me) * | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
CA2537991A1 (en) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
US7552093B2 (en) * | 2003-12-04 | 2009-06-23 | Black Duck Software, Inc. | Resolving license dependencies for aggregations of legally-protectable content |
EP1694865A4 (en) | 2003-12-12 | 2007-06-06 | Bayer Pharmaceuticals Corp | METHOD OF PREDICTING AND PROGNOSING CANCER AND MONITORING ANTICANCER TREATMENT |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
JP2008503560A (ja) | 2004-06-22 | 2008-02-07 | ファイザー・プロダクツ・インク | ジアザビシクロ系のヒスタミン−3受容体アンタゴニスト |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
ATE395905T1 (de) | 2004-08-27 | 2008-06-15 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
NZ553804A (en) | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
EP1797037B1 (en) | 2004-09-29 | 2014-12-17 | Bayer HealthCare LLC | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
WO2006125539A2 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
KR20080018908A (ko) | 2005-05-27 | 2008-02-28 | 바이엘 헬스케어 아게 | 암 치료용 디아릴 우레아 화합물 및 pi3, akt 키나제또는 mtor 억제제 (라파마이신)를 포함하는 병용요법 |
WO2007015947A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
US20090221010A1 (en) * | 2005-10-21 | 2009-09-03 | Elting James J | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
US20090215835A1 (en) * | 2005-10-31 | 2009-08-27 | Scott Wilhelm | Treatment of cancer with sorafenib |
CA2627875A1 (en) * | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Combinations comprising sorafenib and interferon for the treatment of cancer |
KR20080073729A (ko) * | 2005-11-02 | 2008-08-11 | 바이엘 헬스케어 엘엘씨 | 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법 |
CA2628091A1 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007054215A1 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl ureas for treating pulmonary hypertension |
WO2007059154A2 (en) | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
CN101454668A (zh) * | 2005-11-14 | 2009-06-10 | 拜耳医药保健有限责任公司 | 癌症预测与预后以及监测癌症治疗的方法 |
WO2007059155A1 (en) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
WO2007064872A2 (en) | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
DK2111401T3 (da) | 2006-12-20 | 2011-05-30 | Bayer Healthcare Llc | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer |
WO2008089389A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
-
2006
- 2006-02-22 US US11/885,930 patent/US9737488B2/en active Active
- 2006-02-22 NZ NZ561178A patent/NZ561178A/en unknown
- 2006-02-22 SI SI200630863T patent/SI1868579T1/sl unknown
- 2006-02-22 EP EP06707141A patent/EP1868579B1/en not_active Revoked
- 2006-02-22 WO PCT/EP2006/001574 patent/WO2006094626A1/en active Application Filing
- 2006-02-22 BR BRPI0608840A patent/BRPI0608840B8/pt active IP Right Grant
- 2006-02-22 UA UAA200711110A patent/UA93673C2/ru unknown
- 2006-02-22 CN CN200680007187.1A patent/CN101132779B/zh not_active Ceased
- 2006-02-22 AT AT06707141T patent/ATE482693T1/de active
- 2006-02-22 CA CA2601955A patent/CA2601955C/en active Active
- 2006-02-22 CN CN201510055041.5A patent/CN104688697A/zh active Pending
- 2006-02-22 MX MX2007010856A patent/MX2007010856A/es active IP Right Grant
- 2006-02-22 PT PT06707141T patent/PT1868579E/pt unknown
- 2006-02-22 ES ES06707141T patent/ES2351612T3/es active Active
- 2006-02-22 SG SG201001549-3A patent/SG160364A1/en unknown
- 2006-02-22 KR KR1020077020370A patent/KR101335932B1/ko active IP Right Review Request
- 2006-02-22 AU AU2006222365A patent/AU2006222365B2/en active Active
- 2006-02-22 DK DK06707141.5T patent/DK1868579T3/da active
- 2006-02-22 DE DE602006017188T patent/DE602006017188D1/de active Active
- 2006-02-22 JP JP2008500066A patent/JP5304241B2/ja active Active
- 2006-02-22 PL PL06707141T patent/PL1868579T3/pl unknown
- 2006-02-27 GT GT200600096A patent/GT200600096A/es unknown
- 2006-03-03 AR AR20060100820A patent/AR054234A1/es not_active Application Discontinuation
- 2006-03-03 DO DO2006000057A patent/DOP2006000057A/es unknown
- 2006-03-03 MY MYPI20060919A patent/MY162319A/en unknown
- 2006-03-06 PE PE2006000250A patent/PE20061345A1/es active IP Right Grant
- 2006-03-06 UY UY29410A patent/UY29410A1/es not_active Application Discontinuation
- 2006-03-06 TW TW095107345A patent/TWI324928B/zh active
- 2006-03-07 HN HN2006009702A patent/HN2006009702A/es unknown
-
2007
- 2007-08-27 IL IL185517A patent/IL185517A/en active IP Right Grant
- 2007-08-28 CR CR9348A patent/CR9348A/es unknown
- 2007-08-30 CU CU20070203A patent/CU23821A3/es active IP Right Grant
- 2007-09-05 ZA ZA200707638A patent/ZA200707638B/xx unknown
- 2007-09-06 TN TNP2007000341A patent/TNSN07341A1/en unknown
- 2007-10-02 MA MA30267A patent/MA29378B1/fr unknown
- 2007-10-05 NO NO20075042A patent/NO343834B1/no unknown
-
2008
- 2008-08-19 HK HK08109248.3A patent/HK1118019A1/zh unknown
-
2010
- 2010-12-06 HR HR20100674T patent/HRP20100674T1/hr unknown
- 2010-12-10 CY CY20101101138T patent/CY1111065T1/el unknown
-
2015
- 2015-10-22 HK HK15110355.1A patent/HK1209620A1/xx unknown
-
2017
- 2017-08-22 US US15/683,210 patent/US20180036249A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
JP2021038242A (ja) | ルカパリブの高投与力価錠剤 | |
HRP20192064T1 (hr) | Formulacije apiksabana | |
ITMI20001450A1 (it) | Nuova composizione farmaceutica | |
ZA200508361B (en) | Orally disintegrating tablets | |
HRP20161262T1 (hr) | Tablete ulipristal acetata | |
JP2016536285A (ja) | アムロジピン及びバルサルタンを含む安定な医薬組成物 | |
US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
JPS6241646B2 (hr) | ||
JP6009967B2 (ja) | 固形製剤 | |
JP2012529431A (ja) | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 | |
JP2017122056A (ja) | 医薬含有造粒物の製造方法 | |
JP6308938B2 (ja) | 粒状物を製造する方法 | |
US20060222703A1 (en) | Pharmaceutical composition and preparation method thereof | |
CN102349915A (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
JP2007332074A (ja) | 口腔内速崩壊錠およびその製造方法 | |
JP2004522780A5 (hr) | ||
JP2017520619A (ja) | セリチニブ製剤 | |
HRP20191669T1 (hr) | Farmaceutski sastav koji sadrži polimer koji veže fosfate | |
CA3122196A1 (en) | Process for the preparation of easy-to-take tablets containing dry extract of ginkgo biloba leaves | |
JP2005502729A (ja) | 植物抽出物から錠剤を製造するための方法 | |
CA3048968A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
ES2954286T3 (es) | Composiciones de piridostigmina de liberación sostenida |